Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

146
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
146
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.3K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

923
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
923
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.2K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

971
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
971

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bionic sleep therapy for refractory insomnia: a case report and literature review.

BMC anesthesiology·2026
Same author

Impact of Plasticizers on the Microbial Degradation of Polyhydroxybutyrate (PHB).

Toxics·2026
Same author

PHGDH: a metabolic switch in tumor drug resistance and a therapeutic target.

Drug discovery today·2026
Same author

Temperature and salinity controls on the release of manganese from continental margin sediments.

Environmental research·2026
Same author

PHGDH as a therapeutic node: Natural modulators from TCM, degradation pathways, and emerging TPD strategies.

Pharmacological research·2025
Same author

Research progress of drugs targeting GPC3 in cancer therapy.

Bioorganic chemistry·2025
Same journal

Computational Study of ADME-TOx from Selected Phytocompounds of Solanum tuberosum and Cucumis sativus.

Current medicinal chemistry·2026
Same journal

QSAR-Based Strategies for Selective-HDAC6 Inhibitor Development: A Detailed Review.

Current medicinal chemistry·2026
Same journal

Breaking New Ground in Oncology: FDA Acceptance of Vepdegestrant NDA Marks a Milestone for PROTAC Therapies in Breast Cancer.

Current medicinal chemistry·2026
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Research Progress in Competitive Purine Antagonists.

Dan-Xia Ying1, Peng-Cheng Zhao1, Wen Zhang1

  • 1College of Pharmaceutical Science, Zhejiang University of Technology & Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, P.R. China.

Current Medicinal Chemistry
|October 6, 2022
PubMed
Summary
This summary is machine-generated.

Purine drugs are crucial for metabolism and energy, serving as scaffolds for treating respiratory, cardiovascular, and viral diseases. This review classifies current purine drugs by target and details their mechanisms and signaling pathways.

Keywords:
DNA polymeraseGPCRPI3KPurine derivativesanti-tumoranti-viralcGMP-PDE

More Related Videos

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.7K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.8K

Related Experiment Videos

Last Updated: Aug 26, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
09:45

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

10.7K
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
05:07

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

6.8K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Purines are vital nucleotides involved in cellular metabolism, energy supply, and as a core structure in various therapeutic agents.
  • Despite their established importance, recent advancements in purine-based drug discovery have been limited.
  • Purine derivatives are widely utilized as competitive antagonists and precursors in treating diverse diseases.

Purpose of the Study:

  • To classify existing purine drugs based on their therapeutic targets.
  • To elucidate the mechanisms of action and structure-activity relationships of these purine drugs.
  • To detail the cellular signaling pathways and receptor interactions involved in purine drug efficacy.

Main Methods:

  • Systematic classification of marketed purine drugs according to their molecular targets.
  • Review and synthesis of literature on the mechanisms of action and structure-activity relationships.
  • Detailed analysis of purine drug-mediated cell signaling pathways and receptor binding.

Main Results:

  • Purine drugs have been categorized based on their specific cellular targets.
  • Mechanisms of action and structure-activity relationships provide insights into drug design.
  • Specific signaling pathways and receptor interactions critical for therapeutic effects are elucidated.

Conclusions:

  • This review offers a comprehensive overview of current purine drugs, their targets, and mechanisms.
  • Understanding these pathways is crucial for future development of novel purine-based therapeutics.
  • The detailed analysis supports the continued importance of purine scaffolds in drug discovery.